Sonja Fernbach

Sonja Fernbach

Auto-generated profile, based on publicly available information

Sonja Fernbach

Institute of Medical Virology, University of Zurich

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
SFSonja Fernbach
Sonja Fernbach
NMNina K. Mair
Nina K. Mair
IAIrene A. Abela
Irene A. Abela
KGKevin Groen
Kevin Groen
RKRoger Kuratli
Roger Kuratli
SYSabine Yerly
Sabine Yerly
Autoantibodies neutralizing type I interferons (IFN-Is) can underlie infection severity. Here, we trace the development of these autoantibodies at high-resolution using longitudinal samples from 1,876 well-treated individuals living with HIV over a 35-year period. Similar to general populations, ∼1.9% of individuals acquired anti-IFN-I autoantibodies as they aged (median onset ∼63 years). Once detected, anti-IFN-I autoantibodies persisted lifelong, and titers increased over decades. Individuals developed distinct neutralizing and non-neutralizing autoantibody repertoires at discrete times that selectively targeted combinations of IFNα, IFNβ, and IFNω. Emergence of neutralizing anti-IFNα autoantibodies correlated with reduced baseline IFN-stimulated gene levels and was associated with subsequent susceptibility to severe COVID-19 several years later. Retrospective measurements revealed enrichment of pre-existing autoreactivity against other autoantigens in individuals who later developed anti-IFN-I autoantibodies, and there was evidence for prior viral infections or increased IFN at the time of anti-IFN-I autoantibody triggering. These analyses suggest that age-related loss of self-tolerance prior to IFN-I immune-triggering poses a risk of developing lifelong functional IFN-I deficiency.

20 March 2025 in Journal of Experimental Medicine
Verified
Journal Article
Open access
KGKevin Groen
Kevin Groen
RKRoger Kuratli
Roger Kuratli
JEJannik Enkelmann
Jannik Enkelmann
SFSonja Fernbach
Sonja Fernbach
PWPedro D Wendel-Garcia
Pedro D Wendel-Garcia
BHBenjamin Hale
Benjamin Hale
Autoantibodies neutralizing type I interferons (IFN-Is; IFNα or IFNω) exacerbate severe viral disease, but specific treatments are unavailable. With footprint profiling, we delineate two dominant IFN-I faces commonly recognized by neutralizing IFN-I autoantibody–containing plasmas from aged individuals with HIV-1 and from individuals with severe COVID-19. These faces overlap with IFN-I regions independently essential for engaging the IFNAR1/IFNAR2 heterodimer, and neutralizing plasmas efficiently block the interaction of IFN-I with both receptor subunits in vitro. In contrast, non-neutralizing autoantibody–containing plasmas limit the interaction of IFN-I with only one receptor subunit and display relatively low IFN-I–binding avidities, thus likely hindering neutralizing function. Iterative engineering of signaling-inert mutant IFN-Is (simIFN-Is) retaining dominant autoantibody targets created potent decoys that prevent IFN-I neutralization by autoantibody-containing plasmas and that restore IFN-I–mediated antiviral activity. Additionally, microparticle-coupled simIFN-Is were effective at depleting IFN-I autoantibodies from plasmas, leaving antiviral antibodies unaffected. Our study reveals mechanisms of action for IFN-I autoantibodies and demonstrates a proof-of-concept strategy to alleviate pathogenic effects.

22 March 2022 in Cell Reports
Verified
Journal Article
Open access
SFSonja Fernbach
Sonja Fernbach
ESEva E. Spieler
Eva E. Spieler
IBIdoia Busnadiego
Idoia Busnadiego
UKUmut Karakus
Umut Karakus
ALAnouk Lkharrazi
Anouk Lkharrazi
BHBenjamin Hale
Benjamin Hale
Host interferons (IFNs) powerfully restrict viruses through the action of several hundred IFN-stimulated gene (ISG) products, many of which remain uncharacterized. Here, using RNAi screening, we identify several ISG restriction factors with previously undescribed contributions to IFN-mediated defense. Notably, RABGAP1L, a Tre2/Bub2/Cdc16 (TBC)-domain-containing protein involved in regulation of small membrane-bound GTPases, robustly potentiates IFN action against influenza A viruses (IAVs). Functional studies reveal that the catalytically active TBC domain of RABGAP1L promotes antiviral activity, and the RABGAP1L proximal interactome uncovered its association with proteins involved in endosomal sorting, maturation, and trafficking. In this regard, RABGAP1L overexpression is sufficient to disrupt endosomal function during IAV infection and restricts an early post-attachment, but pre-fusion, stage of IAV cell entry. Other RNA viruses that enter cells primarily via endocytosis are also impaired by RABGAP1L, while entry promiscuous SARS-CoV-2 is resistant. Our data highlight virus endocytosis as a key target for host defenses.

26 March 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
IBIdoia Busnadiego
Idoia Busnadiego
MLMarie Lork
Marie Lork
SFSonja Fernbach
Sonja Fernbach
SSSamira Schiefer
Samira Schiefer
NTNikos Tsolakos
Nikos Tsolakos
BHBenjamin Hale
Benjamin Hale
Interferons (IFNs, types I-III) have pleiotropic functions in promoting antiviral and antitumor responses, as well as in modulating inflammation. Dissecting the signaling mechanisms elicited by different IFNs is therefore critical to understand their phenotypes. Here, we use mass spectrometry to investigate the early temporal dynamics of cellular protein phosphorylation in a human lung epithelial cell-line as it responds to stimulation with IFNα2, IFNβ, IFNω, IFNγ, or IFNλ1, representing all IFN types. We report an atlas of over 700 common or unique phosphorylation events reprogrammed by these different IFNs, revealing both previously known and uncharacterized modifications. While the proteins differentially phosphorylated following IFN stimulation have diverse roles, there is an enrichment of factors involved in chromatin remodeling, transcription, and RNA splicing. Functional screening and mechanistic studies identify that several proteins modified in response to IFNs contribute to host antiviral responses, either directly or by supporting IFN-stimulated gene or protein production. Among these, phosphorylation of PLEKHG3 at serine-1081 creates a phospho-regulated binding motif for the docking of 14-3-3 proteins, and together these factors contribute to coordinating efficient IFN-stimulated gene expression independent of early Janus kinase/signal transducer and activator of transcription signaling. Our findings map the global phosphorylation landscapes regulated by IFN types I, II, and III, and provide a key resource to explore their functional consequences.

1 November 2017 in Forensic Science International: Genetics
Verified
Journal Article
Closed access
IGIva Gomes
Iva Gomes
PPPlácido J.P. Pereira
Plácido J.P. Pereira
SHSonja Harms
Sonja Harms
AOAndréa M. Oliveira
Andréa M. Oliveira
PSPeter M. Schneider
Peter M. Schneider
ABAntónio Brehm
António Brehm

24 April 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
MKMatthew J. Kennedy
Matthew J. Kennedy
SFSonja Fernbach
Sonja Fernbach
TSTroels Scheel
Troels Scheel